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SLQYLA domaindeﬁciency virus (SHIV)/macaque model for human immunodeﬁciency virus type
1 has become a useful tool to assess the role of accessory genes in lentiviral pathogenesis. In this study, we
introduced two amino acid changes in the highly conserved SLQYLA domain (to AAQYLA) of the SIV Vif
protein. The resulting virus, SHIVVifAAQYLA, was used to infect three macaques, which were followed for over
six months. Plasma viral loads and circulating CD4+ T cell levels were assessed during the course of infection.
The three macaques inoculated with SHIVVifAAQYLA did not develop signiﬁcant CD4
+ T cell loss over the course
of their infection, had plasma viral RNA loads that were over 100-fold lower than macaques inoculated with
parental SHIVKU-1bMC33, and developed no histological lesions in lymphoid tissues. DNA and RT-PCR analysis
revealed that only a select number of tissues were infected with this virus. Sequence analysis indicates that
the site-directed changes were stable during the ﬁrst three weeks after inoculation but thereafter the S147A
amino acid substitution changed to a threonine in two of three macaques. The L148A substitution remained
stable in the vif ampliﬁed from the PBMC of all three macaques. Sequence analysis of vif, vpu, env and nef
genes revealed G-to-A mutations in the genes ampliﬁed frommacaques inoculated with SHIVVifAAQYLA, which
were higher than in a macaque inoculated with parental SHIVKU-1bMC33. We found that the majority (N85%) of
the G-to-A mutations were in the context of 5′-TC (minus strand) and not 5′-CC, suggestive that one or more
of the rhesus APOBEC3 proteins may be responsible for the observed mutational patterns. The data also
suggest that rhesus APOBEC3G probably accounted for a minority of the mutations since its GG-to-AG
mutational pattern was infrequently detected. Finally, macaques inoculated with SHIVVifAAQYLA developed
immunoprecipitating antibody responses against the virus. The results from this study provide the ﬁrst in
vivo evidence of the importance of the SLQYLA domain in viral pathogenesis and show that targeted
mutations in vif can lead to a persistent infection with G-to-A changes accumulating in the viral genome.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) as well as other
lentiviruses encode for a Vif protein, which has been shown to be
essential for HIV-1 replication in certain cell types. The Vif protein of
HIV-1 was ﬁrst shown to interact with apolipoprotein B mRNA editing
enzyme catalytic polypeptide-like 3G (APOBEC3G; hA3G) (Sheehy
et al., 2002). This protein was found to provide cells with an innate
intracellular anti-retroviral activity that is associated with hypermu-
tation of the viral genome through cytidine deamination (Harris et al.,
2003; Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 2003)..
l rights reserved.This hA3G-induced cytidine deamination results in cytidine to uridine
changes duringminus strand DNA synthesis, which ultimately leads to
G-to-A mutations in the plus strand (Yu et al., 2004a). Several groups
subsequently showed that the Vif protein can prevent hypermutation
by binding to hA3G and targeting this protein for degradation via the
proteasome (Conticello et al., 2003; Dussart et al., 2004; Kao et al.,
2003; Liu et al., 2004; Mariani et al., 2003; Marin et al., 2003; Mehle et
al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003,
2004a, 2004b, 2004c). In addition to A3G, humans have six other A3
genes: hA3A, hA3B, hA3C, hA3DE, hA3F, and hA3H (Jarmuz et al.,
2002). The members of this family either have one (hA3A, hA3C, and
hA3H) or two (hA3B, hA3DE, hA3F and hA3G) Zn+2 coordinating
deaminase domains organized as H-x1-E-x25-31-C-x 2-4-C (with×being
a non-conserved position) (Chiu and Greene, 2008). In addition to the
Fig. 1. Replication of SHIVKU-1bMC33 and SHIVVifAAQYLA in APOBEC3G positive (CEM) and
negative (CEM-SS) cell lines. Cells were inoculatedwith equal amounts of each virus and
levels of p27 in the culture supernatants determined at various times post-inoculation.
(Panel A) Replication of SHIVKU-1bMC33 and SHIVVifAAQYLA in CEM-SS cells. (Panel B)
Replication of SHIVKU-1bMC33 and SHIVVifAAQYLA in CEM cells. (●) SHIVKU-1bMC33;
(▪) SHIVVifAAQYLA.
Fig. 2. Circulating CD4+ T cell levels in macaques inoculated with SHIVKU-1bMC33 and
SHIVVifAAQYLA. (Panel A) The levels of circulating CD4+ T cells in three macaques (RAK10,
●; RCS10, ♦; and RPL10, ▴) following inoculation with SHIVVifAAQYLA. (Panel B) The
levels of circulating CD4+T cells in four macaques (2000, ●; 2001, ■; CM4G, ▴; and
CM4K, ♦; RRH10; ▾) following inoculation with SHIVKU-1bMC33.
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and hA3H have been shown to also inhibit the replication of ΔvifHIV-1
(Dang et al., 2007; Doehle et al., 2005; Wiegand et al., 2004; Yang et
al., 2007; Yu et al., 2004a, 2004b, 2004c; Zheng et al., 2004). Moreover,
ΔvifSIVmac239 is potently restricted by hA3G, hA3F, and hA3H and to a
lesser extent by A3B and A3C and A3DE (Dang et al., 2007; 2008;
Mariani et al., 2003; Virgen and Hatziianou, 2007; Yu et al., 2004a,
2004b, 2004c). While fewer studies have been performed on the
APOBEC3 familymembers inmacaques, one study has also shown that
rhesus macaque rA3G and rA3F inhibit the replication of ΔvifSIVmac
(Zennou and Bieniasz, 2006; Virgen and Hatziianou, 2007).
Sequence analysis of Vif proteins fromdifferent lentiviruses reveals
that there is a highly conserved SLQ(Y/F)LA domain near the carboxyl
terminus. The introduction of mutations in this domain results in
decreased binding of Vif to Elongin C of the Cul5/Elongin B/C E3 ligase
complex and increases A3G incorporation into virions resulting in G-
to-A hypermutation (Kobayashi et al., 2005). However, no studies have
assessed the role of this domain using a non-human primate model of
HIV-1 pathogenesis. Our laboratory has been using the chimericsimian–human immunodeﬁciency (SHIV)/macaque model to study
the role of Vpu and its various domains in CD4+ Tcell loss, virus release
and pathogenesis (Stephens et al., 2002; Singh et al., 2003; Hout et al.,
2005; 2006; Hill et al., 2008). In this study, we constructed a simian–
human immunodeﬁciency virus (SHIV) with amino acid changes in
the highly conserved SLQYLA (SHIVVifAAQYLA) domain and assessed it
for pathogenesis in macaques. Our results show for the ﬁrst time that
the SLQYLA domain has determinants that contribute to the
pathogenicity of SHIV in macaques and that mutations in this domain
result in the accumulation of G-to-A mutations in the viral genome.
Results
Replication of SHIVVifAAQYLA in APOBEC3G positive and negative cell lines
We performed assays to examine the replication of parental
SHIVKU-1bMC33 and SHIVVifAAQYLA in A3G/F positive (CEM) and negative
(CEM-SS) cell lines. Cells were infected with each of the two
viruses and the levels of p27 Gag released into the culture
medium were quantiﬁed using a commercial antigen capture assay.
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parental SHIVKU-1bMC33 (Fig. 1A). However, SHIVVifAAQYLA released less
than 0.5% p27 compared to the parental SHIVKU-1bMC33 in CEM cells
(Fig. 1B). We also examined virions for the incorporation of A3G
following passage in CEM cells. Our results indicate that SHIVVifAAQYLA
but not SHIVKU-1bMC33 incorporated A3G into virions (data not shown).
Disease in macaques inoculated with the SHIVVifAAQYLA
We inoculated three macaques with the SHIVVifAAQYLA. Prior to
inoculation, macaques RAK10, RPL10, and RCS10 had circulating CD4+
cell counts of 2638, 2480, and 3206, respectively. As shown in Fig. 2A,
macaques RAK10, RCS10, and RPL10 developed a slight decrease in the
levels of circulating CD4+ T cell levels at one week post-inoculation
but these rebounded to near pre-inoculation levels by fourweeks post-
inoculation. These macaques maintained high levels of circulating
CD4+ T cells throughout the course of their infection. All three ma-
caques were euthanized at 28 weeks post-inoculation in excellent
condition. At necropsy, RAK10, RPL10, and RCS10 had circulating CD4+
T cell counts of 2427, 1656, and 3021, respectively. This contrasts with
macaques inoculated with parental SHIVKU-1bMC33 (Fig. 2B), which
developed a severe loss of circulating CD4+ T cells. Analysis of the
plasma viral loads of the macaques inoculated with SHIVVifAAQYLA
revealed that during the early peak (1 to 3weeks) of viremia, themean
loadwas 8.52×104 copies per ml (Fig. 3A), approximately 100-fold less
than the macaques inoculated with parental SHIVKU-1bMC33 (Fig. 3B).Fig. 3. Plasma viral loads in macaques inoculated with SHIVKU-1bMC33 and SHIVVifAAQYLA.
(Panel A) Plasma viral loads in threemacaques (RAK10,●; RCS10,♦; RPL10,▴) following
inoculation with SHIVVifAAQYLA. (Panel B) Plasma viral loads in four macaques (2000, ●;
CM4G, ■; CM4K, ▴; and RRH10, ▾) following inoculation with SHIVKU-1bMC33.Following the ﬁrst month of infection, the plasma viral loads in
macaque RPL10 declined faster than macaques RAK10 and RCS10.
Stability of the vif gene mutations during the course of infection
and at necropsy
We assessed the stability of the engineered mutations in the vif
gene during the course of infection. DNA was extracted from PBMC
samples at various times post-inoculation and from lymphoid tissues
at necropsy. The vif sequence was ampliﬁed, directly sequenced and
compared to the input vif sequence of SHIVVifAAQYLA. As shown in
Fig. 4, the vif mutations were stable from one to three weeks post-
inoculation for all three macaques inoculated with SHIVVifAAQYLA, but
by 4 weeks post-inoculation the S147A amino acid substitution
changed to a threonine in two of the macaques RPL10 and RAK10.
Interestingly, this amino acid substitution was mediated by a G-to-A
mutation. DNA from lymphoid organs obtained at necropsy from
RAK10 and RPL10 also showed the A147T mutation whereas macaque
RCS10 maintained the S147A amino acid substitution. The L148A
substitution was found to be stable during the course of infection for
all three macaques and in lymphoid organs analyzed at necropsy.
There were no mutations in this region of vif from RRH10, which was
inoculated with parental SHIVKU-1bMC33.
Macaques inoculated with SHIVVifAAQYLA developed antibody responses
against the virus
At necropsy, we analyzed the plasma for the presence of
immunoprecipitating antibody responses. As shown in Fig. 5, all
three macaques developed immunoprecipitating antibodies against
SHIVKU-1bMC33, although macaque RCS10 developed signiﬁcantly
lower antibody response compared to the other two macaques. In
contrast, a macaque inoculated with parental SHIVKU-1bMC33 (RRH10)
did not develop antibodies to the virus, which is common for
macaques that develop severe CD4+ T cell loss during the acute
phase (b4 weeks) following inoculation with a pathogenic X4 SHIV.
Histological examination of tissues
Tissues from macaques were examined for the presence of
histological lesions consistent with pathogenic X4 SHIV (Stephens
et al., 2002). Histological examination of tissues frommacaque RRH10,
which was inoculated with SHIVKU-1bMC33, revealed severe lymphoid
depletion in both the thymus and lymph nodes and mild lymphoid
depletion in the spleen (Fig. 6). The lymphoid depletion observed in
macaque RRH10 is typical of that observed following inoculation with
the parental SHIVKU-1bMC33 (Stephens et al., 2002). The macaques
inoculated with SHIVVifAAQYLA did not exhibit lesions in any of the 13
visceral organs and CNS. Micrographs of sections from the thymus,
mesenteric lymph node, and spleen from macaque RAK10 are shown
along with micrographs of histological sections from an uninfected
macaque (Fig. 6).
Macaques inoculated with SHIVVifAAQYLA had a decreased tissue
distribution of replicating virus
As the plasma viral loads were decreased in comparison to
macaques inoculated with parental SHIVKU-1bMC33, we wanted to
determine if this was due to infection of select cell populations in one
or more organs, which may not express APOBEC3G. We ﬁrst analyzed
DNA isolated from 13 visceral organs from the SHIVVifAAQYA macaques
for the presence of viral gag sequences by nested DNA PCR. We
previously showed that these oligonucleotide primers were capable of
detecting 1–5 copies of viral DNA (Joag et al., 1994). Generally, we
ﬁnd that nearly all visceral organs from SHIVKU-1bMC33-inoculated
macaques are positive for viral gag sequences in DNA and RNA
Fig. 4. Analysis of the vif gene for the stability of the engineeredmutations. DNAwas isolated from PBMC at 1, 3, 4, 8, 12 and 28 weeks (necropsy) post-inoculation and from lymphoid
organs (thymus, mesenteric lymph node, and inguinal lymph node) at necropsy. The vif gene was ampliﬁed and directly sequenced. Shown at the top are the sequences for both
parental SHIVKU-1bMC33 and SHIVVifAAQYLA.
365K. Schmitt et al. / Virology 383 (2009) 362–372samples (Fig. 7A; macaque RRH10). For the macaques inoculated with
SHIVVifAAQYLA, we found that 6 of 13, 8 of 13, and 12 of 13 organs from
macaques RAK10, RCS10, and RPL10, respectively, were positive forFig. 5. Macaques inoculated with SHIVVifAAQYLA developed antibody responses against
the virus. C8166 cells were inoculated with SHIVKU-1bMC33 for 5 days, starved for
methionine/cysteine and then radiolabeled overnight with 35S-methionine/cysteine.
The culture medium was harvested and used in immunoprecipitation reactions with
plasma from RAK10, RPL10, RCS10 and RRH10 as described in the Materials and
methods section. The immunoprecipitates were washed with 1× RIPA buffer, boiled in
1× sample reducing buffer and proteins separated on 10% SDS-PAGE gels. (Lane 1) SHIV
proteins immunoprecipitated using from an uninfected culture. (Lane 2) SHIV proteins
immunoprecipitated from a positive control plasma sample. (Lane 3) SHIV proteins
immunoprecipitated using RAK10 plasma. (Lane 4) SHIV proteins immunoprecipitated
using RCS10 plasma. (Lane 5) SHIV proteins immunoprecipitated using RPL10 plasma.
(Lane 6) SHIV proteins immunoprecipitated using RRH10 plasma. The molecular weight
standards are shown on the left.viral gag sequences by nested DNA PCR (Figs. 7B–D). The majority of
the organs that were gag positive were lymphoid organs. We next
analyzed RNA isolated from tissues for the presence of RNA using
RT-PCR. The results of this analysis are shown in Fig. 8. We found that
5 of 13, 6 of 13, and 9 of 13 organs from macaques RAK10, RCS10, and
RPL10 were positive for viral gag RNA, respectively. The control
macaque (RRH10), had 12 of 13 and 11 of 13 organs positive for the
presence of viral DNA and RNA gag sequences, respectively. Taken
together, these results indicate that SHIVVifAAQYLA infection was less
widespread in 2 of 3 macaques compared to macaques inoculated
with parental SHIVKU-1bMC33.
Sequence changes vif, vpu, env and nef in primary and secondary
lymphoid organs at necropsy
Awell documented feature of ΔvifHIV-1 infection is the incorpora-
tion of select APOBEC3 proteins into viral particles leading to cytosine
deamination during minus strand DNA synthesis. This results in
hypermutation (guanosine to adenosine transitions) of the viral
genome and inhibition of virus replication. We examined the extent
of G-to-A mutations in viral DNA ampliﬁed from one primary
lymphoid organ (thymus) and several secondary lymphoid organs
(mesenteric, axillary, and inguinal lymph nodes) from the three
macaques inoculated with SHIVVifAAQYLA and one macaque inoculated
with SHIVKU-1bMC33. We analyzed sequences from the vif, vpu, env, and
nef genes. The results of the sequence analyses are shown in Table 1.
The salient features of these analyses were that: a) with the exception
of env, the thymus consistently had the lowest percentage of G-to-A
mutations; b) not all lymphoid organs had signiﬁcant G-to-A
Fig. 6.Histopathology associatedwith SHIVVifAAQYLA infection ofmacaques. Hematoxylin and eosin stains of sections from the thymus (Panels A–C) andmesenteric lymphnode (Panels
D–F) and spleen (Panels G–I) from a SHIVVifAAQYLA-inoculatedmacaque RAK10 (Panels A, D, and G), from an uninfectedmacaque (Panels B, E, and H) and from a SHIVKU-1bMC33-infected
macaque RRH10 (Panels C, F, and I).
366 K. Schmitt et al. / Virology 383 (2009) 362–372mutations; and c) greater than 85% of the G-to-A mutations were in
the context of TCT and not CC. The sequence of vpu ampliﬁed from the
lymphoid tissues of macaque RPL10 is shown as an example (Fig. 9).
Macaque RRH10, (inoculated with SHIVKU-1bMC33) had the fewest G-
to-A mutations in all lymphoid organs, which is similar to other
macaques inoculated with this virus (unpublished observations). The
percentage of mutations was approximately b0.2–0.41% of the
nucleotides analyzed for macaque RRH10. The highest percentage of
G-to-A mutations found in the macaques inoculated with SHIV-
VifAAQYLA was in the nef gene ampliﬁed from macaque RCS10 (5.0%).
Pooled plasma from the two macaques inoculated with SHIVVifAAQYLA
contained low levels of infectious virus when transfused into
a naive macaque
To determine if infectious virus was present in plasma that was not
detected in our infectivity assays, plasma from macaques RAK10, and
RPL10 (2 ml each) were pooled and intravenously inoculated into a
naive macaque, I95. As shown in Fig. 10A, we could detect viral gag
sequences in DNA isolated from PBMC at 0, 1, 2, 3, 4, 5, 6, and 20 weeks
post-inoculation. We also assessed plasma for viral loads using real-
time PCR. As shown in Fig. 11B, viral gag sequences could not be
detected in plasma by real-time RT-PCR (detection limit 100 copies)
fromweeks 0 to 20. The circulating CD4+ T cell levels did not decrease
from pre-inoculation levels (Fig. 10B) and we could not detect
antibodies in the plasma from this macaque at week 9 (data not
shown). At 20 weeks post-inoculation, macaque I95 was sacriﬁced.
DNAwas isolated from 10 visceral organs and used in nested DNA PCR
to detect viral gag sequences. As shown in Fig. 11A, viral gag sequenceswere ampliﬁed from all 10 organs examined. We also isolated RNA
from the same organs for use in RT-PCR to detect viral gag RNA
sequences. As shown in Fig. 11B, the viral RNA was detected in six
organs (liver, kidney, axillary lymph node, small intestine (ileum),
spleen, and tonsil). This indicates that some level of viral replication
was ongoing although we were unable to isolate infectious virus on
CEM-SS or SupT1 cells. Taken together, these results indicate that
pooled plasma contained only low levels of infectious virus that was
controlled by the macaque I95.
Discussion
The results presented here are the ﬁrst to evaluate the role of
domain-speciﬁc mutations in the BC box domain of the vif gene in a
non-human primate model of HIV-1/AIDS. Previous studies have
shown that Vif interacts with elongin C, which has a consensus
sequence of (A,P,S,T)1L2xxx(C,A,S)6xxx(A,I,L,V)10 with the leucine at
position 2 being invariant (Luo et al., 2005). The invariant leucine at
position 2 of this box is critical because mutation of this amino acid to
an alanine residue prevents the interaction of Vif with elongin C
(Kobayashi et al., 2005; Yu et al., 2003; Yu et al., 2004a, 2004b, 2004c).
Since the S147 and L148 amino acids of the SLQYLA domain are
conserved among the primate lentivirus Vif proteins, we chose to
change these amino acids to alanine residues. Our results differ from
those previously reported by Desrosiers et al. (1998), who reported
transient replication of a SIVΔVif in macaques before it was
undetectable in the plasma. At ﬁrst glance the results presented
here and those reported by Desrosiers et al. (1998) might appear to be
conﬂicting. However, there are important differences in the viruses
Fig. 7. Macaques inoculated with SHIVVifAAQYLA had a decreased tissue distribution of virus. DNA was isolated from different organs as indicated at necropsy and ampliﬁed using
nested DNA PCR using oligonucleotides speciﬁc for gag. Samples were run on a 1.5% agarose gel, stained with ethidium bromide and photographed. Shown are the results of the
nested DNA PCR using DNA frommacaques RRH10 (Panel A), RAK10 (Panel B), RCS10 (Panel C) and RPL10 (Panel D). The tissue DNAs analyzed are noted above each lane. The positive
control was gag ampliﬁed from the lymph node tissue DNA from macaque 50O that died of neuroAIDS and the negative control was lymph node tissue DNA from an uninfected
macaque. The markers to the right are in base pairs.
367K. Schmitt et al. / Virology 383 (2009) 362–372used in each study. In the study of Desrosiers et al. (1998), the vif was
truncated (only 28 amino acids were expressed) and the virus was
SIVmac239, which expresses a R5 envelope glycoprotein. The virus
used in this study had site-directed mutations in vif and the viral
background was SHIVKU-1bMC33, which is based on SIVmac239 but
expresses an X4 envelope glycoprotein. It is known that SIVmac239
targets infection of the gut mucosal CD4+ cells, (Veazey et al., 1998)
while previous studies have shown that pathogenic X4 SHIVKU-1bMC33
targets the thymus during the acute phase of infection. Thus, it is
possible that each virus is targeting different populations of cells in
the early stage of infection, which may express differing levels of the
APOBEC3 family members.
The results from this study indicate that macaques inoculated with
SHIVVifAAQYLA developed no signiﬁcant loss of circulating CD4+
T cells and had a 100-fold lower plasma viral loads during the acute
phase of infection, when compared to macaques inoculated with
SHIVKU-1bMC33. Additionally, our analyses revealed fewer tissues
positive for viral gag DNA and RNA sequences in 2 of 3 macaques in
this group, suggesting that SHIVVifAAQYLA was for the most part
controlled by the host. This could be due to the presence of susceptible
cells expressing one of the APOBEC3 family members that could
restrict a virus with these mutations in Vif. The presence of plasma
viral loads in these macaques indicates that virus may have persisted
in populations of cells that probably either did not express A3G/F/DE/
C/B or expressed these proteins at very low levels. These results
correlate with our previous studies that showed restricted expression
of A3G in brain and kidney tissues (Hill et al., 2006; 2007), both of
which are targets for HIV-1, SIV and SHIV (Gattone et al., 1998; Khanet al., 2006; Letendre et al., 2008; Raghavan et al., 1997; Stephens et al.,
2000; Zink and Clements, 2002). Thus, a major question that emerged
was, “Are the viruses produced from these cellular reservoirs
infectious, replication competent viruses?” The gold standard for
detecting small amounts of virus is by inoculation into a naive,
susceptible animal. Passage of plasma from twomacaques into a naive
macaque (I95) revealed the presence of virus in PBMCs of this
macaque at 1 to 20 weeks and in the 10 tissues examined at necropsy,
although the plasma viral loads were below the limits of detection
(100 copies per ml). These results suggest that plasma frommacaques
had infectious virus but it was readily controlled by the macaques.
While none of the three macaques exhibited signiﬁcant histologi-
cal lesions, there were two incongruent observations. The ﬁrst was
that macaque RPL10 had the lowest viral loads but had the most
widespread tissue distribution of viral sequences. While the reason is
unclear, it could be due to greater viral distribution during the early
stage of infection. The second observation was that macaque RCS10
developed less immunoprecipitating antibodies compared with
macaques RPL10 and RAK10. Whether this relates to the inability to
select for the A147T amino acid substitution is currently unknown.
Perhaps the A147T substitution permitted more replication in
macaques RAK10 and RPL10 resulting in a better antigenic stimulus.
It should be noted that virus with the A147T substitution could not be
isolated from the twomacaques inwhich it was observed. Thus, we do
not know if a virus with a TAQYLA motif is capable of causing CD4+
T cell loss, histological lesions and high virus burdens.
Our sequence analysis indicated that not all viral genes ampliﬁed
from the lymphoid tissues had G-to-A mutations that were above
Fig. 8.Macaques inoculated with SHIVVifAAQYLA had a decreased tissue distribution of viral RNA. RNA was isolated from different organs as indicated at necropsy, DNase I treated to
remove residual DNA and used in nested RT-PCR using oligonucleotides described in the Materials and methods. Samples were run on a 1.5% agarose gel, stained with ethidium
bromide and photographed. The results are shown as follows: (Panel A) macaques RRH10; (Panel B) RAK10; (Panel C) RCS10; and (Panel D) RPL10. The tissue RNAs analyzed are noted
above each lane. The positive control was ampliﬁcation of gag from the lymph node tissue RNA from macaque 50O that died of neuroAIDS. The negative control was lymph node
tissue RNA from an uninfected macaque. The markers to the right are in base pairs.
368 K. Schmitt et al. / Virology 383 (2009) 362–372background levels. For the three macaques, a total of 4 tissues
(axillary, mesenteric, and inguinal lymph nodes, thymus) and four
genes (vif, vpu, env and nef) were analyzed. Approximately half (25) ofTable 1




Thymus MLN ALN ILN
RRH10
vif 1/466 (0.21%)a 1/466 (0.21%) 1/466 (0.21%) 1/466 (0.21%)
vpu 2/246 (0.0%) 1/246 (0.4%) 1/246 (0.4%) 1/246 (0.4%)
env 2/490 (0.41%) 0/490 (0.0%) 0/480 (0.0%) 0/480 (0/0%)
nef 1/400 (0.25%) 1/400 (0.25%) 2/400 (0.50%) 0/400 (0.0%)
RAK10
vif 0/466 (0.00%) 16/466 (3.4%) 7/400 (1.50%) 1/466 (0.21%)
vpu 1/246 (0.4%) 4/246 (0.4%) 4/246 (1.63%) 4/246 (1.63%)
env 12/490 (2.44%) 10/490 (2.04%) 12/490 (2.44%) 10/490 (2.04%)
nef 2/400 (0.50%) 1/400 (0.25%) 17/400 (4.25%) 1/400 (0.25%)
RCS10
vif 0/466 (0.0%) 1/466 (0.21%) 8/466 (3.25%) 1/466 (0.21%)
vpu 1/246 (0.4%) 1/246 (0.4%) 4/246 (1.62%) 2/246 (0.8%)
env 10/490 (2.04%) 8/490 (1.63%) 10/490 (2.04%) 12/490 (2.44%)
nef 1/400 (0.25%) 20/400 (5.00%) 2/400 (0.5%) 1/400 (0.25%)
RPL10
vif 3/466 (0.64%) 6/466 (1.28%) 9/466 (1.93%) 8/466 (1.72%)
vpu 3/246 (1.2%) 6/246 (2.4%) 9/246 (3.70%) 8/246 (3.3%)
env 9/490 (1.83%) 8/490 (1.63%) 8/490 (1.63%) 8/490 (1.63%)
nef 1/400 (0.25%) 2/400 (0.5%) 6/400 (1.25%) 4/400 (1.0%)
The ratio of the number of G-to-A nucleotide substitutions/number of bases sequenced
is shown.
a The percentage of G-to-A substitutions are in parentheses.the 48 sequences had G-to-A mutations that were above 1.2% with the
majority of the mutations in the context of 5′-TC. Potential reasons for
this may include that the aliquot of tissue that was examined may
have had archived virus from the initial round of replication, the
viruses ampliﬁed were from a cell type that did not express
APOBEC3G/F, or that the domain-speciﬁc mutations may have
crippled but not completely abolished Vif antiviral activity. Alterna-
tively, it is possible that both deaminase-dependent and deaminase-
independent mechanisms may be present to decrease virus replica-
tion in macaques. The context in which the G-to-A mutations were
found can give clues as to what APOBEC3 member is involved in the
cytidine deamination. Human A3G is known to cause cytidine
deamination with a base preference of 5′-CC (minus strand), A3F a
preference for 5′-TC, and A3DE a preference for T/A-T/A-C-G/T (Dang
et al., 2007; Liddament et al., 2004; Yu et al., 2004a, 2004b, 2004c).
Previous studies showed that A3G and A3F were widely expressed
while a more recent study showed that A3F may not be as widespread
as previously reported (Wiegand et al., 2004; Dang et al., 2007). A3DE
was also shown to be expressed in the same tissues as A3G (Dang
et al., 2007). Of those tissues that showed signiﬁcant G-to-A
mutations, over 85% of the G-to-A mutations were in the context of
5′-TC, suggesting that one or more APOBEC3 proteins were probably
responsible for the majority of the observed mutational patterns with
APOBEC3G and its GG-to-AG mutational pattern accounting for a
minority (b15%) of the observed G-to-A mutations.
Attenuated viruses have been used to prevent many viral di-
seases in humans (smallpox, poliovirus, measles, mumps, rubella,
chickenpox, etc.). It is known that live, attenuated virus vaccines
generally result in better immune responses (both humoral and cell
mediated) that are longer lived when compared to killed virus
Fig. 9. Sequence of the vpu gene ampliﬁed from lymphoid tissues of macaque RPL10. Shown above is the input sequence of the vpu from SHIVKU-1bMC33. The (.) represents identity
with the nucleotide sequence shown above. The underlined sequences represent the context in which the G-to-A mutations occurred.
369K. Schmitt et al. / Virology 383 (2009) 362–372vaccines. However, the major drawback of attenuated virus vaccines is
that live viruses are genetic elements and replication can introduce
mutations that result in reversion of the attenuated phenotype to aFig. 10. Viral loads and circulating CD4+ T cell levels in macaque I95 that was
intravenously inoculated with pooled plasma from macaques RAK10 and RPL10
obtained at necropsy (2 ml each). Blood was obtained at 0 (just prior to inoculation),
1, 2, 3, 4, 5, 6, and 20 weeks after inoculation. The plasma was retained and the
PBMC puriﬁed over Ficoll-Hypaque gradients. The DNA was isolated from the PBMC.
(Panel A) Results of the nested DNA PCR for viral gag using DNA isolated from PBMC.
(Lane 1) 100 base pair markers. (Lane 2) Positive control. (Lanes 3–10) represent gag
sequences ampliﬁed from PBMC isolated from I95 at 0, 1, 2, 3, 4, 5, 6, and 20 weeks post-
inoculation, respectively. (Panel B) Results of the real-time PCR for viral gag sequences
from plasma samples (▴; scale to left) and circulating CD4+ T cell levels (●; scale to
right).pathogenic phenotype. The prime example of this is the live
attenuated poliovirus vaccine (Kew et al., 2005). The major concern
for the use of attenuated lentiviruses has been that it involved the
removal of “non-essential” viral genes such as vpr, vpx, nef or vpu,
which could allow for low level virus replication and the accumulation
of compensatory mutations in other gene and potentially a reversion
to a pathogenic phenotype. The work by Daniel et al. (1992) showed
that deletion of the nef from the pathogenic SIVmac239 resulted in an
attenuated virus that resisted challenge against pathogenic parental
virus. However, the hope that a safe attenuated vaccine could be
developed was soon diminished by the studies showing that inocu-
lation of a SIVmac239 derivative with deletions in vpr, nef and the
negative regulatory element (NRE) could cause AIDS in neonatal
macaques (Baba et al., 1995). This was followed with a study showing
that the same virus could cause disease in both neonatal and adult
macaques (Baba et al., 1999). Despite these setbacks, the vaccines
against SIV (or HIV-1) infection that have shown the most promise
have been those with one or more genes of the virus that have deletedFig. 11. Distribution of viral RNA and DNA sequences in tissues from macaque I95. At
necropsy, tissues were harvested and DNA or RNA isolated and used in nested DNA
(panel A) or nested RT-PCR (panel B). Panel A. Results of the nested DNA PCR for viral
gag using isolated DNA. (Lane 1) Positive control. (Lane 2) Negative control. (Lane 3)
Liver. (Lane 4) Lung. (Lane 5) Kidney. (Lane 6) Mesenteric lymph node. (Lane 7) Axillary
lymph node. (Lane 8) Inguinal lymph node. (Lane 9) Small intestine (ileum). (Lane 10)
Spleen. (Lane 11) Thymus. (Lane 12) Tonsil. (Lane 13) 100 base pair markers. (Panel B)
Results of the nested RT-PCR for viral gag using isolated RNA. (Lane 1) 100 base pair
markers. (Lane 2) Positive control. (Lane 3) Negative control. (Lane 4) Liver. (Lane 5)
Lung. (Lane 6) Kidney. (Lane 7) Mesenteric lymph node. (Lane 8) Axillary lymph node.
(Lane 9) Inguinal lymph node. (Lane 10) Small intestine (ileum). (Lane 11) Spleen. (Lane
12) Thymus. (Lane 13) Tonsil.
370 K. Schmitt et al. / Virology 383 (2009) 362–372or inactivated (Koff et al., 2006). In contrast to Vpr, Vpx, Vpu and Nef,
the Vif protein is required for replication in CD4+ T cells and macro-
phages, the twomajor cell populations that HIV-1 infects productively
(Chiu and Greene, 2008). This suggests that mutations that target one
or more conserved (and functional) domains within Vif may permit
limited replication and generation of effective immune responses
against the virus prior to “self inactivation” through the activities of
various APOBEC3 family members and may represent a novel means
to attenuate lentiviruses for candidate vaccines.
Materials and methods
Cells, plasmids, and viruses
The CEM, and CEM-SS lymphocyte cell lines were used for
transfections and as indicator cells to measure infectivity and
cytopathicity of the viruses used in this study. CEM and CEM-SS cell
lines (obtained from the NIH AIDS Research and Reagents Program)
and C8166 cells were maintained in RPMI-1640, supplemented with
10 mM Hepes buffer pH 7.3, 2 mM glutamine, 5 μg per ml gentamicin
and 10% fetal bovine serum (R10FBS). The derivation of SHIVKU-1bMC33
has been previously described (McCormick-Davis et al., 2000;
Stephens et al., 2002).
Construction of SHIVVifAAQYLA
For the construction of SHIVVifAAQYLA, a Pac I/SphI fragment
(nucleotides 4609 to 5901) from the p5′-SHIV4 was subcloned into the
pGEMT-EZvector (aPac I sitewas introduced into themulti-cloning site).
The serine to alanine substitution at position 147 of Vif was introduced
using oligonucleotides (only sense strand shown) 5′-AAGTACCAGGTAC-
CAGCCCTACAGTACTTA-3′ and the Quick-Change Mutagenesis Kit (Stra-
tagene) according to the manufacturer's instructions. The resulting
plasmid, pGEMPAC-SphALQYLA, was used to change the leucine at posi-
tion 148 to an alanine using oligonucleotides (sense strand shown) 5′-
ACCAGGTACCAGCCGCACAGTACTTAGCAC-3′ and the Quick-Change
Mutagenesis Kit (Stratagene) according to the manufacturer's instruc-
tions. The resulting plasmid, pGEMPAC-SphAAQYLA, was isolated and
digested with PacI/SphI. The isolated fragment was subcloned into
p5′SHIV-4 to generate 5′-SHIVVifAAQYLA andwas sequenced to determine
if the desiredmutations were introduced as expected. To generate virus,
p5′SHIVVifAAQYLA and p3′SHIVKU-1bMC33were digestedwith Sph I and the
two plasmids ligated together with T4 DNA ligase. The resulting ligation
was transfected into CEM-SS cells as previously described (Stephens
et al., 2002; Hout et al., 2004; 2005). Stocks of SHIVKU-1bMC33 and
SHIVVifAAQYLA were prepared and titered in CEM-SS cells and stored
at −86 °C.
Replication of SHIVVifAAQYLA in APOBEC3G positive and negative cell lines
We assessed the replication of SHIVVifAAQYLA in CEN (A3G/F
positive) and CEM-SS (A3G/F negative) cell lines. Cells were infec-
ted with equivalent levels (50 ng) of parental SHIVKU-1bMC33 or
SHIVVifAAQYLA for 4 h at 37 °C. The cells were centrifuged and washed 3
times to remove the inoculum and incubated in fresh medium at 37 °C
for 9 days. Aliquots of culture supernatants were obtained at 0, 1, 3, 5,
7, and 9 days post-inoculation and the levels of p27 assessed using
commercially available p27 antigen capture kits (Zeptometrix).
Macaques analyzed in this study
Five 1–1.5 year old pig-tailed macaques (Macaca nemestrina: 2000;
2001; CM4G; CM4K; RRH10) were intravenously inoculated with 1 ml
of undiluted supernatant from C8166-grown stocks of SHIVKU-1bMC33
containing 104 TCID50 per milliliter. Three additional macaques
(RAK10; RPL10; RCS10) were inoculated with 104 TCID50 SHIVVifAAQYLA(titered in CEM-SS). At necropsy, 2 ml of plasma frommacaques RPL10
and RAK10 were used to inoculate a naive macaque, I95. The animals
were housed in the AAALAC-approved animal facility at the University
of Kansas Medical Center. Blood was collected weekly for the ﬁrst
4 weeks, then at 2 week intervals for the next month, and thereafter at
monthly intervals.
Assays for circulating CD4+ T cells
Alterations in the levels of CD4+ T cells after experimental
inoculations were monitored sequentially by FACS analysis (Becton
Dickinson). T cell subsets were labeled with OKT4 (CD4; Ortho
Diagnostics Systems, Inc), SP34 (CD3; Pharmingen) or FN18 (CD3;
Biosource International) monoclonal antibodies. T cell subsets from a
normal uninfected macaque were always performed at the same time
to serve as a control for the FACS analysis.
Processing of tissue samples at necropsy
At the time of euthanasia (28 weeks for thosemacaques inoculated
with SHIVVifAAQYLA and 20 weeks for macaque I95), all animals in this
study were anesthetized by administration of 10 mg/kg ketamine (IM)
followed by intravenous administration of sodium phenobarbital at
20–30 mg/kg. A laparotomy was performed and the animal exsangui-
nated by aortic canulation and perfusedwith 1 l of cold Ringer's saline.
All aspects of the animal studies were performed according to the
institutional guidelines for animal care and use at the University of
Kansas Medical Center. Lymphoid and non lymphoid tissues (heart,
kidneys, liver, lungs, mesenteric, inguinal and axillary lymph nodes,
pancreas, salivary gland, small intestine, spleen, thymus, and tonsils)
were obtained and aliquots of tissue snap frozen for DNA and RNA
assays. Portions of lymphoid tissues were immersed in HBSS to
quantify levels of infectious virus in tissues.
Analysis of tissues for viral RNA and DNA sequences
DNA was extracted from the visceral organs listed above as
previously described (Hill et al., 2008) and used in nested PCR to
amplify SIV gag sequences. The sensitivity of detection of gagwas 1–5
copies and have been previously described (Joag et al., 1994). The
ampliﬁed product was 240 base pairs. The ampliﬁed product was
visualized by electrophoresis through 1.5% agarose gels and staining
with ethidium bromide.
We also analyzed tissues for the presence of viral RNA, indicative of
actively replicating virus. RNA was extracted from approximately
30 mg of each visceral or CNS tissue using the RNAEasy kit (Qiagen)
and the manufacturer's instructions. RNA samples were digested with
DNase I for 30 min. Samples were run on agarose formaldehyde gels
before and after DNase I treatment to check for the presence of
contaminating DNA. RT-PCR ampliﬁcation of the extracted RNA was
performed using the Titan One RT-PCR kit (Roche) and the manufac-
turer's instructions. Each reaction used one microgram of total RNA
and was ampliﬁed using oligonucleotide primers speciﬁc for the SIV
gag gene. The oligonucleotides used for the ﬁrst round of ampliﬁcation
were 5′-CGTCATCTGGTGCATTCACG-3′ (sense) and 5′-CTGATTAATGT-
CATAGGGGGTGC-3′ (antisense), which are complementary to bases
1343–1362 and 1636–1658 of SIVmac239, respectively. The nested
SIVmac239 primers used were 5′-CACGCAGAAGAGAAAGTGAAACAC-3′
(sense) and 5′-GGTGCAACCTTCTGACAGTGC-3′ (antisense), which
are correspond to bases 1359–1382 and 1620–1640, respectively.
As a control, β-actin was ampliﬁed using the oligonucleotides
5′-TCATGTTTGAGACCTTCAACACCCCAG-3′ (sense) and 5′-CCAAGAAG-
GAAGGCTGGAAGAGTGCC-3′ (antisense). The reactions were per-
formed with an Applied Systems 2720 Thermal Cycler using the
following thermal proﬁle: 42 °C for 30 min, 1 cycle; 94 °C for 2 min, 1
cycle; 94 °C for 30 s, 55 °C for 30 s, and 68 °C for 45 s, 10 cycles; 94 °C
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the initial reaction mixture was then added to a nested PCR mixture
containing gag primers and performed with the following thermal
proﬁle: 95 °C for 1 min, 48 °C for 2 min, and 72 °C for 3 min, 35 cycles.
The ampliﬁed gag fragment is 281 base pairs.
Sequence analysis of the vif, vpu, env, and nef genes
To determine the stability of the mutations that were introduced
into vif, the vif gene was ampliﬁed from PBMCs at different time
points during infection and from several tissue DNA samples taken at
necropsy. One microgram of extracted genomic DNA was used in a
DNA polymerase chain reaction (Takara, Madison, WI) following the
manufacturer's instructions. Oligonucleotides were employed that
ampliﬁed the entire vif, vpu, and nef genes and a region of env from
nucleotides 704–1530 in gp120. For sequence analysis, the PCR
products from three separate PCR reactions were pooled and
separated by electrophoresis in a 1.5% agarose gel, isolated, and each
PCR reaction directly sequenced. Cycle sequencing reactions using the
BigDye Terminator Cycle Sequencing Ready Reaction Kit with
AmpliTaq DNA polymerase, FS (PE Applied Biosystems, Foster City,
CA) sequence detection was conducted with an Applied Biosystems
377 Prism XL automated DNA sequencer and visualized using the ABI
Editview program. Sequences were compared to the sequence of
SHIVKU-1bMC33. A total of 466, 246, 490, and 400 nucleotides were
analyzed from the vif, vpu, env, and nef genes, respectively using the
SE Central Software package.
Plasma virus loads
Plasma viral RNA loads were determined on RNA extracted from
500 μl of EDTA-treated plasma. Virus was pelleted in an ultracen-
trifuge (Beckman SW55Ti, 100,000 ×g, 2 h) and RNA extracted using
the Qiagen viral RNA kit (Qiagen, Valencia, CA). RNA samples were
analyzed by real-time RT-PCR using gag primers and a 5′FAM and
3′TAMRA labeled Taqman probe that was homologous to the SIV gag
gene as previously described (Hofmann-Lehmann et al., 2000). Stan-
dard curveswere preparedusing a series of twelve ten-fold dilutions of
viral RNA of known concentration. The sensitivity of the assaywas 100
RNA equivalents per ml. Samples were analyzed in triplicate and the
number of RNA equivalents were calculated per ml of plasma.
Immunoprecipitation assays
To determine if the macaques developed antibodies to SHIV
proteins following inoculation, the plasma obtained at necropsy was
used in immunoprecipitation assays. C8166 cells were inoculated with
approximately 104 TCID50 of SHIVKU-1bMC33 for 4 days. The cells were
then incubated in methionine/cysteine-free media for 2 h and
radiolabeled labeled with 500 μCi of 35S-methionine/cysteine for
15 h. The cells were lysed in 1 ml of 1× RIPA buffer and nuclei were
removed by centrifugation. The cell lysates were incubated overnight
at 4 °C with 10 μl of plasma from each macaque and protein A
Sepharose beads. The immunoprecipitates bound to the beads were
washed three times in 1× RIPA, resuspended in 75 μl of 2× sample
reducing buffer, and boiled for 5min. Proteinswere separated on a 10%
SDS-PAGE gel and proteins visualized by autoradiography. Controls
included pooled prebleed plasma from macaques RAK10, RPL10, and
RCS10 (negative control) and plasma from macaques that had been
previously inoculated with non-pathogenic SHIV-4 (positive control).
Acknowledgments
The work reported here is supported by grants NIH grant AI64019
and AI51981 to E.B.S.We thank Dr. Joyce Slusser for assistancewith the
ﬂow cytometry. The anti-APOBEC3G was kindly provided by the NIHAIDS Research and Reference Reagent Program. We thank members of
the KUMC Biotechnology Support Facility and the Northwestern
Genomics Core Facility for their assistance with the sequence analysis
and oligonucleotide synthesis.
References
Baba, T.W., Jeong, Y.S., Pennick, D., Bronson, R., Greene, M.F., Ruprecht, R.M., 1995.
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.
Science 267, 1820–1825.
Baba, T.W., Liska, V., Khimani, A.H., Ray, N.B., Dailey, P.J., Penninck, D., Bronson, R.,
Greene, M.F., McClure, H.M., Martin, L.N., Ruprecht, R.M., 1999. Live attenuated,
multiply deleted simian immunodeﬁciency virus causes AIDS in infant and adult
macaques. Nat. Med. 5, 194–203.
Chiu, Y.L., Greene, W.C., 2008. The APOBEC3 cytidine deaminases: an innate defensive
network opposing exogenous retroviruses and endogenous retroelements. Annu.
Rev. Immunol. 26, 317–335.
Conticello, S.G., Harris, R.S., Neuberger, M.S., 2003. The Vif protein of HIV triggers degra-
dationof thehumanantiretroviralDNAdeaminaseAPOBEC3G. Cur. Biol.13, 2009–2013.
Dang, Y., Wang, X., Esselman, W.J., Zheng, Y.-H., 2007. Identiﬁcation of APOBEC3DE as
anotherantiretroviral factor fromthehumanAPOBEC family. J. Virol. 80,10522–10533.
Dang, Y., Siew, L.M., Wang, X., Han, Y., Lampen, R., Zheng, Y.H., 2008. Human cytidine
deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283, 11606–11614.
Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., Desrosiers, R.C., 1992. Protective
effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258,
1938–1941.
Desrosiers, R.C., Lifson, J.D., Gibbs, J.S., Czajak, S.C., Howe, A.Y., Arthur, L.O., Johnson, R.P.,
1998. Identiﬁcation of highly attenuated mutants of simian immunodeﬁciency
virus. J. Virol. 72, 1431–1437.
Doehle, B.P., Schafer, A., Cullen, B.R., 2005. Human APOBEC3B is a potent inhibitor of
HIV-1 infectivity and is resistant to Vif. Virology 339, 281–288.
Dussart, S., Courcoul, M., Bessou, G., Douaisi, M., Duverger, Y., Vigne, R., Decroly, E., 2004.
The Vif protein of human immunodeﬁciency virus type 1 is posttranslationally
modiﬁed by ubiquitin. Biochem. Biophys. Res. Com. 315, 66–72.
Gattone II, V.H., Tian, C., Zhuge, W., Sahni, M., Narayan, O., Stephens, E.B., 1998. SIV-
associated nephropathy in rhesus macaques infected with lymphocyte-tropic
SIVmac239. AIDS Res. Hum. Retrovir. 14, 1163–1180.
Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K., Watt, I.N.,
Neuberger, M.S., Malim, M.H., 2003. DNA deaminationmediates innate immunity to
retroviral infection. Cell 113, 803–809.
Hill, M.S., Mulcahy, E.R., Gomez, M.L., Pacyniak, E., Berman, N.E.J., Stephens, E.B., 2006.
APOBEC3G expression is restricted to neurons in the brains of pig-tailed macaques.
AIDS Res. Hum. Retrovir. 22, 541–550.
Hill, M.S., Ruiz, A., Gomez, L.M., Miller, J.M., Berman, N.E.J., Stephens, E.B., 2007.
APOBEC3G expression is restricted to epithelial cells of the proximal convoluted
tubules and is not expressed in the glomeruli of macaques. J. Histochem. Cytochem.
55, 63–70.
Hill, M.S., Ruiz, A., Pacyniak, E., Pinson, D.M., Culley, N., Yen, B., Wong, S.W., Stephens, E.B.,
2008. Modulation of the severe CD4+ Tcell loss caused by a pathogenic simian human
immunodeﬁciency virus by replacement of the the subtype B vpuwith the vpu from a
subtype C HIV-1 clinical isolate. Virology 371, 86–97.
Hofmann-Lehmann, R., Swenerton, R.K., Liska, V., Leutenegger, C.M., Lutz, H., McClure,
H.M., Ruprecht, R.M., 2000. Sensitive and robust one-tube real-time reverse
transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of
one- versus two-enzyme systems. AIDS Res. Hum. Retrovir. 16, 1247–1257.
Hout, D.R., Gomez, M.L., Pacyniak, E., Gomez, L.M., Inbody, S.H., Mulcahy, E.R., Culley, N.,
Pinson, D.M., Powers, M.F., Wong, S.W., Stephens, E.B., 2005. Scrambling of the
amino acids within the transmembrane domain of Vpu results in a simian–human
immunodeﬁciency virus (SHIVTM) that is less pathogenic for pig-tailed macaques.
Virology 339, 56–69.
Hout, D.R., Gomez, M.L., Pacyniak, E., Gomez, L.M., Fegley, B., Mulcahy, E.R., Hill, M.S.,
Culley, N., Pinson, D.M., Nothnick, W., Powers, M.F., Wong, S.W., Stephens, E.B.,
2006. Substitution of the transmembrane domain of Vpu in simian–human
immunodeﬁciency virus (SHIVKU1bMC33) with that of M2 of inﬂuenza A results in
a virus that is sensitive to inhibitors of theM2 ion channel and is pathogenic for pig-
tailed macaques. Virology 344, 541–559.
Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., Navaratnam, N.,
2002. An anthropoid-speciﬁc locus of orphan C to U RNA-editing enzymes on
chromosome 22. Genomics 79, 285–296.
Joag, S.V., Stephens, E.B., Adams, R.J., Foresman, L., Narayan, O., 1994. Pathogenesis of
SIVmac infection in Chinese and Indian rhesusmacaques: effects of splenectomy on
virus burden. Virology 200, 436–446.
Kao, S., Khan, M.A., Miyagi, E., Plishka, R., Buckler-White, A., Strebel, K., 2003. The
human immunodeﬁciency virus type 1 Vif protein reduces intracellular expression
and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infec-
tivity. J. Virol. 77, 11398–11407.
Kew, O.M., Sutter, R.W., de Gourville, E.M., Dowdle,W.R., Pallansch, M.A., 2005. Vaccine-
derived polioviruses and the endgame strategy for global polio eradication. Annu.
Rev. Microbiol. 59, 587–635.
Khan, S., Haragsim, L., Laszik, Z.G., 2006. HIV-associated nephropathy. Adv. Chronic
Kidney Dis. 13, 307–313.
Kobayashi, M., Takaori-Kondo, A., Miyauchi, Y., Iwai, K., Uchiyama, T., 2005. Ubiquitina-
tion of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential
for Vif function. J. Biol. Chem. 280, 18573–18578.
372 K. Schmitt et al. / Virology 383 (2009) 362–372Koff, W.C., Johnson, P.R., Watkins, D.I., Burton, D.R., Lifson, J.D., Hasenkrug, K.J.,
McDermott, A.B., Schultz, A., Zamb, T.J., Boyle, R., Desrosiers, R.C., 2006. HIV vaccine
design: insights from live attenuated SIV vaccines. Nat. Immunol. 7, 19–23.
Lecossier, D., Bouchonnet, F., Clavel, F., Hance, A.J., 2003. Hypermutation of HIV-1 DNA
in the absence of the Vif protein. Science 300, 1112.
Letendre, S., McCutchan, J.A., Ellis, R.J., 2008. Neurologic complications of HIV disease
and their treatment. Top. HIV Med. 16, 15–22.
Liddament, M.T., Brown, W.L., Schumacher, A.J., Harris, R.S., 2004. APOBEC3F properties
and hypermutation preferences indicate activity against HIV-1 in vivo. Cur. Biol. 14,
1385–1391.
Liu, B., Yu, X., Luo, K., Yu, Y., Yu, X.F., 2004. Inﬂuence of primate lentiviral Vif and
proteasome inhibitors on human immunodeﬁciency virus type 1 virion packaging
of APOBEC3G. J. Virol. 78, 2072–2081.
Luo, K., Xiao, Z., Ehrlich, E., Yu, Y., Liu, B., Zheng, S., Yu, X.F., 2005. Primate lentiviral virion
infectivity factors are substrate receptors that assemblewith cullin5-E3 ligase through
a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102, 11444–11449.
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., Trono, D., 2003. Broad
antiretroviral defence by human APOBEC3G through lethal editing of nascent
reverse transcripts. Nature 424, 99–103.
Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C.,
Nymark-McMahon, H., Landau, N.R., 2003. Species-speciﬁc exclusion of APOBEC3G
from HIV-1 virions by Vif. Cell 114, 21–31.
Marin, M., Rose, K.M., Kozak, S.L., Kabat, D., 2003. HIV-1 Vif protein binds the editing
enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398–1403.
McCormick-Davis, C., Dalton, S.B., Hout, D.R., Singh, D.K., Berman, N.E., Yong, C., Pinson,D.M.,
Foresman, L., Stephens, E.B., 2000. A molecular clone of simian–human immunodeﬁ-
ciency virus (ΔvpuSHIVKU-1bMC33) with a truncated, non-membrane-bound vpu results
in rapid CD4+ T cell loss and neuroAIDS in pig-tailed macaques. Virology 272, 112–126.
Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., Gabuzda, D., 2004. Vif overcomes
the innate antiviral activity of APOBEC3G by promoting its degradation in the
ubiquitin–proteasome pathway. J. Biol. Chem. 279, 7792–7798.
Raghavan, R., Stephens, E.B., Joag, S.V., Adany, I., Pinson, D.M., Li, Z., Jia, F., Sahni, M.,
Leung, K., Foreman, L., Narayan, O., 1997. Neuropathogenesis of chimeric simian/
human immunodeﬁciency virus infection in pig-tailed and rhesus macaques. Brain
Pathol. 7, 851–861.
Sheehy, A.M., Gaddis, N.C., Choi, J.D., Malim, M.H., 2002. Isolation of a human gene that
inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418,
646–650.
Sheehy, A.M., Gaddis, N.C., Malim, M.H., 2003. The antiretroviral enzyme APOBEC3G is
degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404–1407.
Singh, D.K., Grifﬁn, D.M., Pacyniak, E., Jackson, M., Werle, M.J., Wisdom, B., Sun, F., Hout,
D.R., Pinson, D.M., Gunderson, R.S., Powers, M.F., Wong, S.W., Stephens, E.B., 2003.
The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4+
T cell loss caused by the simian–human immunodeﬁciency virus SHIVKU-lbMC33 in
pig-tailed macaques. Virology 313, 435–451.Stephens, E.B., Tian, C., Dalton, S.B., Gattone II, V.H., 2000. Simian–human immunode-
ﬁciency virus-associated nephropathy in macaques. AIDS Res. Hum. Retrovir. 16,
1295–1306.
Stephens, E.B., McCormick, C., Pacyniak, E., Grifﬁn, D., Pinson, D.M., Sun, F., Nothnick, W.,
Wong, S.W., Gunderson, R., Berman, N.E., Singh, D.K., 2002. Deletion of the vpu
sequences prior to the env in a simian–human immunodeﬁciency virus results in
enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques.
Virology 293, 252–261.
Stopak, K., de Noronha, C., Yonemoto, W., Greene, W.C., 2003. HIV-1 Vif blocks the
antiviral activity of APOBEC3G by impairing both its translation and intracellular
stability. Mol. Cell 12, 591–601.
Veazey, R.S., DeMaria, M., Chalifoux, L.V., Shvetz, D.E., Pauley, D.R., Knight, H.L.,
Rosenzweig, M., Johnson, R.P., Desrosiers, R.C., Lackner, A.A., 1998. Gastrointestinal
tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.
Science 280, 427–431.
Virgen, C.A., Hatziioannou, T., 2007. Antiretroviral activity and Vif sensitivity of rhesus
macaque APOBEC3 proteins. J. Virol. 81, 13932–13937.
Wiegand, H.L., Doehle, B.P., Bogerd, H.P., Cullen, B.R., 2004. A second human
antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
EMBO J. 23, 2451–2488.
Yang, Y., Guo, F., Cen, S., Kleiman, L., 2007. Inhibition of initiation of reverse transcription
in HIV-1 by human APOBEC3F. Virology 365, 92–100.
Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., Yu, X.F., 2003. Induction of APOBEC3G
ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302,
1056–1060.
Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Cofﬁn, J.M.,
Landau, N.R., 2004a. Single-strand speciﬁcity of APOBEC3G accounts for minus-
strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435–442.
Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D., Landau, N.R., 2004b. APOBEC3B and
APOBEC3C are potent inhibitors of simian immunodeﬁciency virus replication.
J. Biol. Chem. 279, 53379–53386.
Yu, Y., Xiao, Z., Ehrlich, E.S., Yu, X., Yu, X.F., 2004c. Selective assembly of HIV-1 Vif-Cul5-
ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and
upstream cysteines. Genes Dev. 18, 2867–2872.
Zennou, V., Bieniasz, P.D., 2006. Comparative analysis of the antiretroviral activity of
APOBEC3G and APOBEC3F from primates. Virology 349, 31–40.
Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C., Gao, L., 2003. The
cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1
DNA. Nature 424, 94–98.
Zheng, Y.H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., Peterlin, B.M., 2004. Human
APOBEC3F is another host factor that blocks human immunodeﬁciency virus type 1
replication. J. Virol. 78, 6073–6076.
Zink, M.C., Clements, J.E., 2002. A novel simian immunodeﬁciency virus model that
provides insight into mechanisms of human immunodeﬁciency virus central
nervous system disease. J. Neurovirol. (Suppl. 2), 42–48.
